BTK Inhibitor Downregulates IL-17 Secretion and Enhances CD20mb Sensitivity to ABC Type Diffuse Large B-cell Lymphoma via CYLD/NF-kB Signaling Pathway

View Full Paper

Ask AI

Bookmark

Authors

Discussion

BTK inhibitors improve sensitivity to CD20 in ABC DLBCL, suggesting their potential role in overcoming Rituximab resistance.

Combination therapy with BTK inhibitors and Rituximab reduces IL-17 secretion and enhances cytotoxicity against ABC DLBCL cells.
Significant downregulation of Th17 cell proportion and IL-17 secretion were observed when combining BTK inhibitors with Rituximab.
Both acalabrutinib and zanubrutinib inhibited phosphorylation of NF-κB-p65 in CD4+ T cells, impacting signaling pathways.
In vivo results showed that zanubrutinib reduced tumor volume and Th17 cells alongside IL-17 levels in mice, highlighting therapeutic potential.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

BTK inhibitors improve sensitivity to CD20 in ABC DLBCL, suggesting their potential role in overcoming Rituximab resistance.

Combination therapy with BTK inhibitors and Rituximab reduces IL-17 secretion and enhances cytotoxicity against ABC DLBCL cells.
Significant downregulation of Th17 cell proportion and IL-17 secretion were observed when combining BTK inhibitors with Rituximab.
Both acalabrutinib and zanubrutinib inhibited phosphorylation of NF-κB-p65 in CD4+ T cells, impacting signaling pathways.
In vivo results showed that zanubrutinib reduced tumor volume and Th17 cells alongside IL-17 levels in mice, highlighting therapeutic potential.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark